Main content

    Hematologic Oncology Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov



    Leukemia  |  Multiple Myeloma


    Active Trials

    Leukemia

    Title: A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacititdine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Decscription: Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a morphologically confirmed diagnosis of myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1117

    Back to top

    Multiple Myeloma

    Title: A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
    Decscription: This randomized phase II trial studies how well two doses of carfilzomib work with dexamethasone in treating patients with relapsed or refractory multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have a confirmed diagnosis of symptomatic multiple myeloma and must be relapsed or refractory
    Status: Contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1304

    Title: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
    Decscription: This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who are diagnosed with symptomatic standard-risk multiple myeloma (SR-MM)
    Status: Call site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study ECOG E1A11

    Title: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
    Decscription: This phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who are diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 60 months
    Status: Call site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study ECOG E3A06

    • updated October 2014

    Back to top